In this issue of Blood, Byrd et al provide an important update on the prolonged ef ficacy and the limited and reducing toxicity of the single-agent Bruton tyrosine kinase inhibitor ibrutinib in chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma patients who are followed for a median time of 3 years from start of treatment.
Forconi, F. (2015). Three years of ibrutinib in CLL. BLOOD, 125(16), 2455-2456 [10.1182/blood-2015-03-630772].
Three years of ibrutinib in CLL
FORCONI, FRANCESCO
2015-01-01
Abstract
In this issue of Blood, Byrd et al provide an important update on the prolonged ef ficacy and the limited and reducing toxicity of the single-agent Bruton tyrosine kinase inhibitor ibrutinib in chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma patients who are followed for a median time of 3 years from start of treatment.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
Utilizza questo identificativo per citare o creare un link a questo documento:
https://hdl.handle.net/11365/997795
Attenzione
Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo